PharVision Advisers LLC Makes New Investment in Danaher Corporation $DHR

PharVision Advisers LLC purchased a new position in shares of Danaher Corporation (NYSE:DHR) in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 1,384 shares of the conglomerate’s stock, valued at approximately $284,000.

A number of other large investors have also recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in Danaher by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 59,981,088 shares of the conglomerate’s stock worth $12,296,123,000 after acquiring an additional 230,966 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Danaher by 3.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate’s stock worth $4,016,404,000 after purchasing an additional 612,154 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Danaher by 2.3% in the 1st quarter. Bank of New York Mellon Corp now owns 8,783,485 shares of the conglomerate’s stock valued at $1,800,614,000 after buying an additional 194,466 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Danaher by 11.4% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,677,032 shares of the conglomerate’s stock valued at $1,303,163,000 after buying an additional 579,046 shares during the last quarter. Finally, Invesco Ltd. boosted its holdings in shares of Danaher by 44.5% in the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate’s stock valued at $965,259,000 after buying an additional 1,450,703 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Trading Up 0.6%

Shares of Danaher stock opened at $200.32 on Friday. The business has a fifty day simple moving average of $201.93 and a two-hundred day simple moving average of $199.41. Danaher Corporation has a 1 year low of $171.00 and a 1 year high of $279.90. The company has a market capitalization of $143.44 billion, a price-to-earnings ratio of 42.62, a P/E/G ratio of 2.78 and a beta of 0.75. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The business had revenue of $5.94 billion during the quarter, compared to the consensus estimate of $5.83 billion. During the same quarter last year, the firm posted $1.72 EPS. The company’s quarterly revenue was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Research analysts forecast that Danaher Corporation will post 7.63 EPS for the current year.

Insiders Place Their Bets

In other Danaher news, Director Teri List sold 2,778 shares of the stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the transaction, the director owned 20,751 shares in the company, valued at $4,379,706.06. This trade represents a 11.81% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 11.10% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Royal Bank Of Canada set a $241.00 price objective on Danaher in a report on Tuesday. Scotiabank raised Danaher from a “sector perform” rating to a “sector outperform” rating and set a $275.00 price objective for the company in a report on Friday, July 11th. Wells Fargo & Company cut their price objective on Danaher from $210.00 to $205.00 and set an “equal weight” rating for the company in a report on Wednesday, July 23rd. Wall Street Zen raised Danaher from a “hold” rating to a “buy” rating in a report on Friday, June 27th. Finally, UBS Group cut their price objective on Danaher from $240.00 to $225.00 and set a “buy” rating for the company in a report on Wednesday, July 23rd. Seventeen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $246.35.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.